BPI-371153 vs Envafolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
BPI-371153
Developed by Betta Pharmaceuticals Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05341557 (registry estimate)
No aligned efficacy figure on record for this race.
Envafolimab
Marketed by Suzhou Alphamab and partners
NCT05068427 · Phase 2 · completed
The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05024214 (registry estimate)
Reported efficacy
objective response rate (ORR) (Response is assessed once every 8 weeks, assessed up to 24 weeks.): Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months (not_applicable)
Result source: NCT05068427
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BPI-371153 | Envafolimab |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06123754 |
| OS, median | —Not reported | —Trial running · NCT06123754 |
| ORR | —Not reported | —Trial running · NCT06123754 |
| Duration of response, median | —Not reported | —Trial running · NCT06123754 |
PFS, median
- BPI-371153
- —Not reported
- Envafolimab
- —Trial running · NCT06123754
OS, median
- BPI-371153
- —Not reported
- Envafolimab
- —Trial running · NCT06123754
ORR
- BPI-371153
- —Not reported
- Envafolimab
- —Trial running · NCT06123754
Duration of response, median
- BPI-371153
- —Not reported
- Envafolimab
- —Trial running · NCT06123754
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BPI-371153: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-371153's landscape · Envafolimab's landscape